Bhatnagar, A., Marin, M. P., Lischalk, J. W., Koh, M. J., Agazzi, S., Suy, S., Harris, B. T., Sharma, S. T., Aulisi, E., Anaizi, A., Khattab, M. H., Jean, W. C., Collins, S. P., & Collins, B. T. (2025). Fractionated robotic radiosurgery for unfavorable nonfunctioning pituitary macroadenoma: 5-year outcomes from a single institution protocol. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1519445

Shuryak, I., Wang, E., & Brenner, D. J. (2024). Understanding the impact of radiotherapy fractionation on overall survival in a large head and neck squamous cell carcinoma dataset: a comprehensive approach combining mechanistic and machine learning models. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1422211

White, D., Schiller, G. J., Madan, S., Lentzsch, S., Chubar, E., Lavi, N., Van Domelen, D. R., Bentur, O. S., & Baljevic, M. (2024). Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1352281

Tugend, M., Dattero, J., Shore, T., Korobeynikov, V., & Sekula, R. F. (2024). Primary central nervous system post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation: a case report. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1284577

Qunaj, L., May, M. S., Neugut, A. I., & Herzberg, B. O. (2023). Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1252516

Bauer, S., Larkin, J., Hodi, F. S., Stephen, F., Kapiteijn, E. H. W., Schwartz, G. K., Calvo, E., Yerramilli-Rao, P., Piperno-Neumann, S., & Carvajal, R. D. (2023). A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.975642

Lacuna, K., Bose, S., Ingham, M., & Schwartz, G. (2023). Therapeutic advances in leiomyosarcoma. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1149106

Xiang, X., Guo, F., Li, G., Ma, L., Zhu, X., Abdulla, Z., Li, J., Zhang, J., & Huang, M. (2023). Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1015962

Deb, D., Zhu, S., LeBlanc, M. J., & Danino, T. (2022). Assessing chemotherapy dosing strategies in a spatial cell culture model. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.980770

Olazagasti, C., Ehrlich, M., & Seetharamu, N. (2022). One size does not fit all: Evaluating disparities in lung cancer screening eligibility amongst the Hispanic population. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.995408

Duca, R. B., Massillo, C., Farré, P. L., Graña, K. D., Moro, J., Gardner, K., Lacunza, E., & De Siervi, A. (2022). Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.997457

Khan, S., Patel, S. P., Shoushtari, A. N., Ambrosini, G., Cremers, S., Lee, S., Franks, L., Singh-Kandah, S., Hernandez, S., Sender, N., Vuolo, K., Nesson, A., Mundi, P., Izar, B., Schwartz, G. K., & Carvajal, R. D. (2022). Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.975643

Wei, A. Z., Uriel, M., Porcu, A., Manos, M. P., Mercurio, A. C., Caplan, M. M., Hulse, L., Seedor, R. S., Holovatska, M., Francis, J., Khan, S. A., McDonnell, D. E., Bogomolny, D., Sato, T., Marr, B. P., Haq, R., Orloff, M., Shoushtari, A., & Carvajal, R. D. (2022). Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.961517

Khan, S., Lutzky, J., Shoushtari, A. N., Jeter, J., Marr, B., Olencki, T. E., Cebulla, C. M., Abdel-Rahman, M., Harbour, J. W., Sender, N., Nesson, A., Singh-Kandah, S., Hernandez, S., King, J., Katari, M. S., Dimapanat, L., Izard, S., Ambrosini, G., Surriga, O., … Carvajal, R. D. (2022). Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.976837

Liu, Y., Liu, Y., Ye, S., Feng, H., & Ma, L. (2022). Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.985484

Gordon, K. G., Carvajal, R. D., Graham, S. L., & Houghton, O. M. (2022). The reporting of uveal melanoma cases to the cancer registry in North Carolina. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.877599

Brown, A., Buss, E. J., Chin, C., Liu, G., Lee, S., Rao, R., Taback, B., Wiechmann, L., Horowitz, D., Choi, J. C., Katz, L. M., & Connolly, E. P. (2022). Targeted Intraoperative Radiotherapy (TARGIT-IORT) for Early-Stage Invasive Breast Cancer: A Single Institution Experience. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.788213

Tourigny, D. S., Zucker, M., Kim, M., Russo, P., Coleman, J., Lee, C.-H., Carlo, M. I., Chen, Y.-B., Hakimi, A. A., Kotecha, R. R., & Reznik, E. (2022). Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.910147

Llanos, A. A. M., Li, J., Tsui, J., Gibbons, J., Pawlish, K., Nwodili, F., Lynch, S., Ragin, C., & Stroup, A. M. (2022). Variation in Cancer Incidence Rates Among Non-Hispanic Black Individuals Disaggregated by Nativity and Birthplace, 2005-2017: A Population-Based Cancer Registry Analysis. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.857548

Tolaney, S. M., Beeram, M., Beck, J. T., Conlin, A., Dees, E. C., Puhalla, S. L., Rexer, B. N., Burris, H. A., Jhaveri, K., Helsten, T., Becerra, C., Kalinsky, K., Moore, K. N., Manuel, A. M., Lithio, A., Price, G. L., Chapman, S. C., Litchfield, L. M., & Goetz, M. P. (2022). Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.810023

Roytman, M., Kim, S., Glynn, S., Thomas, C., Lin, E., Feltus, W., Magge, R. S., Liechty, B., Schwartz, T. H., Ramakrishna, R., Karakatsanis, N. A., Pannullo, S. C., Osborne, J. R., Knisely, J. P. S., & Ivanidze, J. (2022). PET/MR Imaging of Somatostatin Receptor Expression and Tumor Vascularity in Meningioma: Implications for Pathophysiology and Tumor Outcomes. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.820287

Gong, Z., Platek, M. E., Till, C., Goodman, P. J., Tangen, C. M., Platz, E. A., Neuhouser, M. L., Thompson, I. M., Santella, R. M., & Ambrosone, C. B. (2022). Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.808715

Stonesifer, C. J., Djavid, A. R., Grimes, J. M., Khaleel, A. E., Soliman, Y. S., Maisel-Campbell, A., Garcia-Saleem, T. J., Geskin, L. J., & Carvajal, R. D. (2021). Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.734354